Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use.
Danese
Silvio
S
Mocciaro
Filippo
F
Guidi
Luisa
L
Scribano
Maria Lia
ML
Comberlato
Michele
M
Annese
Vito
V
Colombo
Elisabetta
E
Stefanelli
Tommaso
T
Marzo
Manuela
M
Vangeli
Marcello
M
Pulitano'
Raffaella
R
Manca
Aldo
A
Armuzzi
Alessandro
A
Malesci
Alberto
A
Prantera
Cosimo
C
Cottone
Mario
M
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000068582:Certolizumab Pegol; D003424:Crohn Disease / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage*; D066298:In Vitro Techniques; D000069285:Infliximab; D008297:Male; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D012008:Recurrence; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D011092:Polyethylene Glycols; D000069285:Infliximab; D000068582:Certolizumab Pegol